Proteomics analysis reveals biomarkers in extracellular vesicles from patients with visceral leishmaniasis, suggesting monitoring can improve treatment outcomes.
Key Points
132 proteins were differentially expressed between patients with active leishmaniasis and those successfully treated, indicating potential biomarkers.
Pathway analysis associated findings with pathogenic mechanisms and effective treatment pathways for visceral leishmaniasis.
Analysis utilized LC-MS/MS on extracellular vesicles from patients at various treatment stages, followed by ELISA for validation.
Results point to the potential of plasma EV-derived biomarkers in patient management, with implications for monitoring treatment success.